Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 6/20 | 1.00 |
| ▸ | GABRB1 | P18505 | 5/20 | 1.00 |
| ▸ | CA1 | P00915 | 2/20 | 0.64 |
| ▸ | CA2 | P00918 | 2/20 | 0.64 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4644161 | 0.88 | GABRA1 (0.78) | GABRA1GABRB1CA1CA2GABRB2 | |
| SCHEMBL13997556 | 0.86 | GABRA1 (0.75) | GABRA1GABRB1CA1CA2GABRB2 | |
| SCHEMBL9967745 | 0.84 | GABRA1 (0.72) | GABRA1GABRB1CA1CA2GABRB2 | |
| SCHEMBL282221 | 0.84 | GABRA1 (0.72) | GABRA1GABRB1CA1CA2GABRB2 | |
| SCHEMBL28687967 | 0.82 | GABRA1 (0.68) | GABRA1GABRB1CA1CA2GABRB2 | |
| SCHEMBL28687966 | 0.82 | GABRA1 (0.68) | GABRA1GABRB1CA1CA2GABRB2 | |
| SCHEMBL18878389 | 0.81 | GABRA1 (0.67) | GABRA1GABRB1CA1CA2GABRB2 | |
| SCHEMBL19130448 | 0.81 | GABRA1 (0.67) | GABRA1GABRB1CA1CA2GABRB2 | |
| SCHEMBL22004173 | 0.80 | GABRA1 (0.64) | GABRA1GABRB1CA1CA2GABRB2 | |
| SCHEMBL10322298 | 0.80 | GABRA1 (0.64) | GABRA1GABRB1CA1CA2GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160095823-A1 | METHODS OF USING PROPOFOL DERIVATIVES FOR ANALGESIA | THE UNIVERSITY OF LIVERPOOL (GB) | 2016-04-07 | — | — | US | claimed |
| CN-103896743-A | 2,6-diisopropyl-4-fluorophenol or salt and crystal form thereof as well as preparation method and application thereof | SICHUAN HAISCO PHARMACEUTICAL CO LTD | 2014-07-02 | — | — | CN | claimed |
| EP-1965780-A2 | SUBSTITUTED PHENOL DERIVATIVES AS ANALGESICS | THE UNIVERSITY OF LIVERPOOL (GB) | 2008-09-10 | — | — | EP | claimed |
| WO-2007071967-A2 | SUBSTITUTED PHENOL DERIVATIVES AS ANALGESICS | THE UNIVERSITY OF LIVERPOOL (GB) | 2007-06-28 | — | — | WO | claimed |
| US-20070142477-A1 | ANALGESIA | THE UNIVERSITY OF LIVERPOOL (GB) | 2007-06-21 | — | — | US | claimed |
| CN-119350256-A | Substituted phenol compound and preparation method and application thereof | 中国药科大学 | 2025-01-24 | — | — | CN | disclosed |
| US-12121498-B2 | Allosteric enhancing compound of GABAA receptor and preparation and use thereof | XI'AN LIBANG ZHAOXIN BIOTECHNOLOGY CO., LTD (CN) | 2024-10-22 | — | — | US | disclosed |
| EP-3845517-B1 | GABA A RECEPTOR ALLOSTERIC ENHANCER COMPOUND AND PREPARATION AND USE THEREOF | XIAN LIBANG ZHAOXIN BIOTECHNOLOGY CO LTD (CN) | 2024-05-01 | — | — | EP | disclosed |
| CN-116693580-A | Anthracene skeleton phenol oxygen single metallocene bimetallic catalyst, preparation method and application | 万华化学集团股份有限公司 | 2023-09-05 | — | — | CN | disclosed |
| CN-113801004-A | Phenyl bisphenol derivative, preparation method and medical application thereof | 四川海思科制药有限公司 | 2021-12-17 | — | — | CN | disclosed |
| CN-109415285-B | Phenyl bisphenol derivative, preparation method and medical application thereof | 四川海思科制药有限公司 | 2021-12-14 | — | — | CN | disclosed |
| US-20210315836-A1 | Allosteric Enhancing Compound of GABAA Receptor and Preparation and Use Thereof | XI'AN LIBANG ZHAOXIN BIOTECHNOLOGY CO., LTD (CN) | 2021-10-14 | — | — | US | disclosed |
| US-6110962-A | FOR TREATING INSULIN RESISTANCE, TYPE II DIABETES, HYPERGLYCEMIA, MODULATING INSULIN LEVELS IN MAMMALS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-08-29 | — | — | US | disclosed |
| WO-1999058521-A1 | 11-ARYL-BENZO[B]NAPHTHO[2,3-D]FURANS AND 11-ARYL-BENZO[B]NAPHTHO[2,3-D]THIOPHENES USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-11-18 | — | — | WO | disclosed |
| US-5965763-A | Biphenyl compounds | HOECHST MARION ROUSSEL (FR) | 1999-10-12 | — | — | US | disclosed |
| US-5827887-A | 5-ALPHA REDUCTASE INHIBITORS | ROUSSEL UCLAF (FR) | 1998-10-27 | — | — | US | disclosed |
| EP-0757982-A1 | Biphenylic compounds, process for their preparations and intermediates for this process, their use as 5-alpha-reductase inhibitors and pharmaceutical compositions containing them | ROUSSEL UCLAF (FR) | 1997-02-12 | — | — | EP | disclosed |
| US-4311839-A | Benzisothiazole and naphtho-1,2-thiazine compounds | POLAROID CORPORATION (US) | 1982-01-19 | — | — | US | disclosed |
| US-4181660-A | 3-Substituted benz[d]isothiazole-1,1-dioxides | POLAROID CORPORATION (US) | 1980-01-01 | — | — | US | disclosed |
| US-4178447-A | Novel synthesis of 3,3-substituted dihydrobenzisothiazole-1,1-dioxides and -2,3-dihydronaphtho-1,2-thiazine-1,1-dioxides | POLAROID CORPORATION (US) | 1979-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315836-A1 | Allosteric Enhancing Compound of GABAA Receptor and Preparation and Use Thereof | GABRP, GABRA1, GABRB1 | GABRA1 2/4885GABRB1 3/4885CA1 2617/4885 |
| US-20160095823-A1 | METHODS OF USING PROPOFOL DERIVATIVES FOR ANALGESIA | GRIN3A, OPRL1, GRIK5 | GABRA1 9/4885GABRB1 29/4885CA1 257/4885 |
| US-12121498-B2 | Allosteric enhancing compound of GABAA receptor and preparation and use thereof | GABRP, GABRA1, GABRB1 | GABRA1 2/4885GABRB1 3/4885CA1 2617/4885 |
| US-20070142477-A1 | ANALGESIA | GRIN3A, OPRL1, GABRA5 | GABRA1 6/4885GABRB1 32/4885CA1 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.